# SpyGlass Pharma, Inc. (SGP)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/spyglass-pharma-inc/ JSON: https://steadybase.io/company/spyglass-pharma-inc.json Checked Nov 21, 2026. Latest filing read: Nov 12, 2026.

## Company

- Legal name: SpyGlass Pharma, Inc.
- Ticker: SGP (Nasdaq)
- SEC CIK: 0001778922
- Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
- Headquarters: Irvine, CA
- Fiscal year ends: December 31
- SEC filer category: <br>Emerging growth company
- Website: spyglasspharma.com
- Investor relations: https://ir.spyglasspharma.com/
- LinkedIn: https://www.linkedin.com/company/spyglasspharma
- Next earnings date: Feb 4, 2027

## Key facts

- Operating income: -$41.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/0001778922-26-000020-index.html
- Net income: -$39.9M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/0001778922-26-000020-index.html
- SG&A: $12.3M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/0001778922-26-000020-index.html
- Employees: 65 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/sgp-20251231.htm
- Shares outstanding: 33,461,450 as of Nov 2, 2026 (10-Q filed Nov 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000056/0001778922-26-000056-index.html
- Auditor: Deloitte & Touche LLP, Costa Mesa, CA, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/sgp-20251231.htm

## Business

SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.

Source: Press release "About" paragraph, https://www.sec.gov/Archives/edgar/data/1778922/000177892226000052/exhibit991-8kprx101926.htm

## Officers and directors

- Patrick H. Mooney, Chief Executive Officer. LinkedIn: https://linkedin.com/in/patrick-mooney-63032ab. Source: Form 4 filed Feb 9, 2026, https://www.sec.gov/Archives/edgar/data/1778922/000210688626000004/0002106886-26-000004-index.htm
- Jean-Frédéric Viret, Ph.D., Chief Financial Officer. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/sgp-20251231.htm
- Jean-Frederic Viret, Chief Financial Officer. LinkedIn: https://linkedin.com/in/jeanviret. Source: Form 4 filed Feb 9, 2026, https://www.sec.gov/Archives/edgar/data/1778922/000142756926000008/0001427569-26-000008-index.htm
- James Dennewill, Chief Operating Officer. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/sgp-20251231.htm
- James Robert Dennewill Jr., Chief Operating Officer. Source: Form 4 filed Feb 9, 2026, https://www.sec.gov/Archives/edgar/data/1778922/000210689526000004/0002106895-26-000004-index.htm
- Chetan Pujara, Ph.D., Chief Research and Development Officer. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/sgp-20251231.htm
- Chetan Pratap Pujara, Chief R&D Officer. Source: Form 4 filed Feb 9, 2026, https://www.sec.gov/Archives/edgar/data/1778922/000210689726000005/0002106897-26-000005-index.htm
- Ali Behbahani, M.D., Director. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/sgp-20251231.htm
- Habib J. Dable, Director. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/sgp-20251231.htm
- Malik Y. Kahook, M.D., Director. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/sgp-20251231.htm
- Patrick Mooney, Director. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/sgp-20251231.htm

## Recent 8-K events

- Nov 12, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000055/sgp-20261111.htm
- Oct 19, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000052/sgp-20261019.htm
- Oct 1, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000049/sgp-20261001.htm
- Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000044/sgp-20260806.htm
- May 14, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000033/sgp-20260514.htm
- Mar 26, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000018/sgp-20260326.htm
- Mar 9, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000004/sgp-20260309.htm
- Feb 13, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1778922/000162828026008073/spyglass-form8xk502fx2025c.htm
- Feb 9, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1778922/000162828026006460/spyglassclosing8-k.htm

## Insider trades (Form 4)

- Nov 16, 2026: Capital Nexus Fund L.P. RA III (Director) bought 1,000 shares, about $32,430. Source: https://www.sec.gov/Archives/edgar/data/1778922/000123191926001605/0001231919-26-001605-index.htm
- Nov 16, 2026: Capital Management L.P. Ra (Director) bought 1,000 shares, about $32,430. Source: https://www.sec.gov/Archives/edgar/data/1778922/000123191926001605/0001231919-26-001605-index.htm
- Nov 16, 2026: Peter Kolchinsky (Director) bought 1,000 shares, about $32,430. Source: https://www.sec.gov/Archives/edgar/data/1778922/000123191926001605/0001231919-26-001605-index.htm
- Nov 16, 2026: Capital Healthcare Fund LP RA (Director) bought 1,000 shares, about $32,430. Source: https://www.sec.gov/Archives/edgar/data/1778922/000123191926001605/0001231919-26-001605-index.htm
- Nov 16, 2026: Rajeev M. Shah (Director) bought 1,000 shares, about $32,430. Source: https://www.sec.gov/Archives/edgar/data/1778922/000123191926001605/0001231919-26-001605-index.htm
- Feb 9, 2026: Bilal Arshad Khan (Director) bought 135,000 shares, about $2.2M. Source: https://www.sec.gov/Archives/edgar/data/1778922/000210804426000006/0002108044-26-000006-index.htm
- Feb 9, 2026: Geoffrey B. Pardo (Director) bought 312,500 shares, about $5.0M. Source: https://www.sec.gov/Archives/edgar/data/1778922/000175314326000006/0001753143-26-000006-index.htm
- Feb 9, 2026: Peter Kolchinsky (Director) bought 3,690,000 shares, about $59.0M. Source: https://www.sec.gov/Archives/edgar/data/1778922/000123191926000135/0001231919-26-000135-index.htm
- Feb 9, 2026: Rajeev M. Shah (Director) bought 3,690,000 shares, about $59.0M. Source: https://www.sec.gov/Archives/edgar/data/1778922/000123191926000135/0001231919-26-000135-index.htm
- Feb 9, 2026: Capital Nexus Fund L.P. RA III (Director) bought 3,690,000 shares, about $59.0M. Source: https://www.sec.gov/Archives/edgar/data/1778922/000123191926000135/0001231919-26-000135-index.htm
- Feb 9, 2026: Capital Healthcare Fund LP RA (Director) bought 3,690,000 shares, about $59.0M. Source: https://www.sec.gov/Archives/edgar/data/1778922/000123191926000135/0001231919-26-000135-index.htm
- Feb 9, 2026: Capital Management L.P. Ra (Director) bought 3,690,000 shares, about $59.0M. Source: https://www.sec.gov/Archives/edgar/data/1778922/000123191926000135/0001231919-26-000135-index.htm
- Feb 9, 2026: Ali Behbahani (Director) bought 937,500 shares, about $15.0M. Source: https://www.sec.gov/Archives/edgar/data/1778922/000119312526046676/0001193125-26-046676-index.htm
- Feb 9, 2026: Kirk G. Nielsen (Director) bought 165,000 shares, about $2.6M. Source: https://www.sec.gov/Archives/edgar/data/1778922/000119312526045029/0001193125-26-045029-index.htm

## Latest filings

- 8-K filed Oct 19, 2026: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000052/sgp-20261019.htm
- 10-K filed Mar 26, 2026: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/sgp-20251231.htm
- 10-Q filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000045/sgp-20260630.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

